Genprex Inc (GNPX)

$1.88 -0.04 (-2.08%)
Market Cap 6.28M
Revenue (ttm) 0.00
Net Income (ttm) -21.11M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 252,700
Avg Vol 1,164,084
Day's Range N/A - N/A
Shares Out 3.12M
Stochastic %K 17%
Beta -0.77
Analysts Strong Buy
Price Target $7.50

Company Profile

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqor...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 774 4679
Address:
3300 Bee Cave Road, Suite 650-227, Austin, United States
W2Cap
W2Cap Mar. 21 at 12:55 PM
$GNPX Company trades at 4.36 million, meaning a 5x from here is 21.8 million in market cap. Peanuts still if they get good news from the FDA, a partnership, or any real traction - particularly with a 2.2m float. Now of course if you want to buy a beaten down microcap bio company there's thousands out there to choose from. None are having members of congress buying up shares consistently. The upside is insane IF they can execute.
0 · Reply
MB76
MB76 Mar. 20 at 8:36 PM
$GNPX Why stack at $2 when you can stack at $1?
2 · Reply
BennyBenneth
BennyBenneth Mar. 20 at 1:55 PM
$GNPX Under 2$ is stacking sale
0 · Reply
MB76
MB76 Mar. 20 at 11:44 AM
$GNPX 👇This guy
0 · Reply
DarkKingTrade
DarkKingTrade Mar. 19 at 9:44 PM
$GNPX Those who wait patiently will become rich!
1 · Reply
MB76
MB76 Mar. 19 at 2:56 PM
$GNPX Have they announced more dilution yet?
0 · Reply
W2Cap
W2Cap Mar. 19 at 2:21 PM
$GNPX
0 · Reply
BennyBenneth
BennyBenneth Mar. 19 at 1:37 PM
$GNPX Accumulation zone kicked in
0 · Reply
AimHighnuwillhitsomewer
AimHighnuwillhitsomewer Mar. 19 at 10:09 AM
$GNPX bad investment
0 · Reply
DarkKingTrade
DarkKingTrade Mar. 19 at 2:29 AM
$GNPX Big News Soon!
1 · Reply
Latest News on GNPX
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Mar 18, 2026, 7:00 AM EDT - 3 days ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Genprex to Participate at BIO Europe Spring 2026

Mar 10, 2026, 7:00 AM EDT - 11 days ago

Genprex to Participate at BIO Europe Spring 2026

Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer

Feb 23, 2026, 8:00 AM EST - 26 days ago

Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer

Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Feb 10, 2026, 8:00 AM EST - 5 weeks ago

Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Genprex Provides Clinical Update on Diabetes Gene Therapy Program

Jan 7, 2026, 7:00 AM EST - 2 months ago

Genprex Provides Clinical Update on Diabetes Gene Therapy Program

Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

Jan 6, 2026, 7:00 AM EST - 2 months ago

Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer

Nov 24, 2025, 7:00 AM EST - 4 months ago

Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer

Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials

Nov 19, 2025, 7:00 AM EST - 4 months ago

Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials

Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Nov 18, 2025, 7:00 AM EST - 4 months ago

Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

Nov 4, 2025, 7:00 AM EST - 4 months ago

Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules

Oct 28, 2025, 11:19 AM EDT - 5 months ago

Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 28, 2025, 7:00 AM EDT - 5 months ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules

Oct 23, 2025, 8:12 AM EDT - 5 months ago

Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 23, 2025, 7:00 AM EDT - 5 months ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Sep 2, 2025, 8:30 AM EDT - 7 months ago

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

Aug 18, 2025, 9:29 AM EDT - 7 months ago

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

Genprex Issues Stockholder Letter and Provides 2025 Corporate Update

Aug 4, 2025, 8:30 AM EDT - 8 months ago

Genprex Issues Stockholder Letter and Provides 2025 Corporate Update

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 24, 2025, 9:25 AM EDT - 9 months ago

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 23, 2025, 9:00 AM EDT - 9 months ago

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex to Participate at BIO 2025 International Convention

Jun 3, 2025, 7:00 AM EDT - 10 months ago

Genprex to Participate at BIO 2025 International Convention

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

May 29, 2025, 7:00 AM EDT - 10 months ago

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

May 28, 2025, 7:00 AM EDT - 10 months ago

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

May 7, 2025, 7:00 AM EDT - 11 months ago

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

May 6, 2025, 7:00 AM EDT - 11 months ago

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting

Apr 30, 2025, 7:30 AM EDT - 11 months ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Apr 29, 2025, 7:30 AM EDT - 11 months ago

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

Apr 28, 2025, 7:30 AM EDT - 11 months ago

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Apr 24, 2025, 8:15 AM EDT - 11 months ago

Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings

Apr 22, 2025, 8:15 AM EDT - 11 months ago

Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

Mar 26, 2025, 8:15 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Mar 25, 2025, 8:15 AM EDT - 1 year ago

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex to Participate at BIO Europe Spring 2025

Mar 4, 2025, 8:15 AM EST - 1 year ago

Genprex to Participate at BIO Europe Spring 2025

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Feb 19, 2025, 8:15 AM EST - 1 year ago

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Genprex Provides Update on Diabetes Gene Therapy Program

Feb 18, 2025, 8:15 AM EST - 1 year ago

Genprex Provides Update on Diabetes Gene Therapy Program

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Feb 13, 2025, 8:15 AM EST - 1 year ago

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Jan 23, 2025, 8:00 AM EST - 1 year ago

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 9:15 AM EST - 1 year ago

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Dec 16, 2024, 9:15 AM EST - 1 year ago

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

Nov 20, 2024, 9:29 AM EST - 1 year ago

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Nov 5, 2024, 9:29 AM EST - 1 year ago

Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Genprex to Participate in 2024 BIO Europe Conference

Oct 31, 2024, 9:29 AM EDT - 1 year ago

Genprex to Participate in 2024 BIO Europe Conference

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma

Oct 28, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma

Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive

Oct 24, 2024, 9:29 AM EDT - 1 year ago

Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive

Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Oct 15, 2024, 9:29 AM EDT - 1 year ago

Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 10, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Oct 7, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes

Sep 23, 2024, 9:29 AM EDT - 1 year ago

Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes

Genprex Announces Formation of Mesothelioma Clinical Advisory Board

Sep 19, 2024, 9:29 AM EDT - 1 year ago

Genprex Announces Formation of Mesothelioma Clinical Advisory Board

Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes

Sep 4, 2024, 9:29 AM EDT - 1 year ago

Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes

Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials

Aug 15, 2024, 9:30 AM EDT - 1 year ago

Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials

W2Cap
W2Cap Mar. 21 at 12:55 PM
$GNPX Company trades at 4.36 million, meaning a 5x from here is 21.8 million in market cap. Peanuts still if they get good news from the FDA, a partnership, or any real traction - particularly with a 2.2m float. Now of course if you want to buy a beaten down microcap bio company there's thousands out there to choose from. None are having members of congress buying up shares consistently. The upside is insane IF they can execute.
0 · Reply
MB76
MB76 Mar. 20 at 8:36 PM
$GNPX Why stack at $2 when you can stack at $1?
2 · Reply
BennyBenneth
BennyBenneth Mar. 20 at 1:55 PM
$GNPX Under 2$ is stacking sale
0 · Reply
MB76
MB76 Mar. 20 at 11:44 AM
$GNPX 👇This guy
0 · Reply
DarkKingTrade
DarkKingTrade Mar. 19 at 9:44 PM
$GNPX Those who wait patiently will become rich!
1 · Reply
MB76
MB76 Mar. 19 at 2:56 PM
$GNPX Have they announced more dilution yet?
0 · Reply
W2Cap
W2Cap Mar. 19 at 2:21 PM
$GNPX
0 · Reply
BennyBenneth
BennyBenneth Mar. 19 at 1:37 PM
$GNPX Accumulation zone kicked in
0 · Reply
AimHighnuwillhitsomewer
AimHighnuwillhitsomewer Mar. 19 at 10:09 AM
$GNPX bad investment
0 · Reply
DarkKingTrade
DarkKingTrade Mar. 19 at 2:29 AM
$GNPX Big News Soon!
1 · Reply
W2Cap
W2Cap Mar. 18 at 7:58 PM
$GNPX And yet the congressman of the biggest biotech hub state is buying. I trust congressional members picking trades vs random fintwit accounts.
1 · Reply
Jpeel1972
Jpeel1972 Mar. 18 at 6:23 PM
$GNPX there’s not been a company to survive with as many RS’s as this. Sadly
0 · Reply
W2Cap
W2Cap Mar. 18 at 6:20 PM
$GNPX TIMMMEEEYYYYY
1 · Reply
MB76
MB76 Mar. 18 at 3:41 PM
$GNPX Hey PUMPERS, what happed to your nickel you were PUMPING in the morning?
0 · Reply
MB76
MB76 Mar. 18 at 3:39 PM
$GNPX 👇This guy obviously hasn’t been here long or he would have been fleeced in February 24 when they did a 1-40 reverse split. Then diluted, and just did another 1-50 reverse split in October of 25. It’s dall they do. Dilute, reverse split, wash and repeat. Twice in 18 months and repeats ever since the scam company started! This ISNT the CEO’s personal check book!!!!!
0 · Reply
Greed8Good
Greed8Good Mar. 18 at 1:55 PM
$GNPX And im not the only one 😉
1 · Reply
Greed8Good
Greed8Good Mar. 18 at 1:54 PM
$GNPX Im here because i believe in this company thats it, Long term investor not a pumper
0 · Reply
MB76
MB76 Mar. 18 at 1:43 PM
$GNPX With this company one thing is true,
0 · Reply
MB76
MB76 Mar. 18 at 1:39 PM
$GNPX This guy is a PATHETIC PUMPER!
0 · Reply
MB76
MB76 Mar. 18 at 1:35 PM
$GNPX If you own it, Sell it!!
2 · Reply
MB76
MB76 Mar. 18 at 1:31 PM
$GNPX
0 · Reply
MB76
MB76 Mar. 18 at 1:30 PM
$GNPX PUMPING AGAIN! RUN
0 · Reply